Search research articles
Contact Us
Filters
Showing results (21-30 of 25) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 25 results.
Tumori
|
May 27, 2026
Hospice admission of cancer patients receiving disease-modifying therapies near the end of life: implications for eligibility criteria
Carla Bettini, Andrea Carlini, Laura Fabbri, et al.
Medical Oncology (Northwood, London, England)
|
June 6, 2022
Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833)
Isacco Desideri, Sara Lucidi, Giulio Francolini, et al.
Therapeutic Advances in Drug Safety
|
April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
Stefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
Breast (Edinburgh, Scotland)
|
October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
Marzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
Cancers
|
September 27, 2025
Older Age Does Not Predict Inadequate Pain Management in Cancer Patients: A Multicenter Prospective Analysis from Italian Radiotherapy Departments (ARISE-Study)
Costanza M Donati, Erika Galietta, Francesco Cellini, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 25) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 25 results.
Tumori
|
May 27, 2026
Hospice admission of cancer patients receiving disease-modifying therapies near the end of life: implications for eligibility criteria
Carla Bettini, Andrea Carlini, Laura Fabbri, et al.
Medical Oncology (Northwood, London, England)
|
June 6, 2022
Use of an alfa-lipoic, Methylsulfonylmethane, Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase inhibitors-related arthralgia management (AIA): a prospective phase II trial (NCT04161833)
Isacco Desideri, Sara Lucidi, Giulio Francolini, et al.
Therapeutic Advances in Drug Safety
|
April 29, 2026
The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
Stefania Crucitta, Paola Cinacchi, Irene Bargagna, et al.
Breast (Edinburgh, Scotland)
|
October 25, 2022
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
Marzia Del Re, Stefania Crucitta, Claudia Omarini, et al.
Cancers
|
September 27, 2025
Older Age Does Not Predict Inadequate Pain Management in Cancer Patients: A Multicenter Prospective Analysis from Italian Radiotherapy Departments (ARISE-Study)
Costanza M Donati, Erika Galietta, Francesco Cellini, et al.
Page
of 3